Pricing Log in Create free account
Saturday 17 October 2026 Export SOLV’s income statement to Excel — free account

Solventum Corporation

SOLV Healthcare Medical Instruments & Supplies

Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.

85.81 2.05 −2.33%
Market cap
$15.0B
P/E
10.4×
Fwd P/E
39.0×
Dividend yield
—
F-score
5/9
Altman Z
2.22
Beneish M
−2.07
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Solventum Corporation (SOLV) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Jun 30, 2026 P1I2: 26 added · 4 removed · 26 modified
P2I1A: no comparison — the earlier filing's Item cannot be compared 		Receivables outpacing revenue
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Aug 5, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jul 16, 2026 5.02 Departure or appointment of directors or officers Officer departure
8-K Jun 2, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 21, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
8-K May 15, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K May 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Mar 20, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 13 added · 21 removed · 43 modified
1A: 21 added · 32 removed · 77 modified
7: 42 added · 26 removed · 35 modified
8-K Feb 26, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 16, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 17, 2025 5.02 Departure or appointment of directors or officers
8-K Sep 8, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 1, 2025 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Aug 22, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.